Published online Aug 27, 2013. doi: 10.4254/wjh.v5.i8.417
Revised: July 4, 2013
Accepted: August 12, 2013
Published online: August 27, 2013
Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Although the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and has a key role in HCC decision-making process. However, radiological assessment of HCC treatment efficacy is often controversial. There are few doubts on the evaluation of surgical resection; in fact, all known tumor sites should be removed. However, an unenhancing partial linear peripheral halo, in most cases, surrounding a fluid collection reducing in size during follow-up is demonstrated in successfully resected tumor with bipolar radiofrequency electrosurgical device. Efficacy assessment of locoregional therapies is more controversial and differs between percutaneous ablation (e.g., radiofrequency ablation and percutaneous ethanol injection) and transarterial treatments (e.g., conventional transarterial chemoembolization, transarterial chemoembolization with drug eluting beads and radioembolization). Finally, a different approach should be used for new systemic agent that, though not reducing tumor mass, could have a benefit on survival by delaying tumor progression and death. The purpose of this brief article is to review HCC imaging appearance after treatment.
Core tip: Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Moreover, recent studies have underlined the potential of antiangiogenetic treatment in patients with untreatable, unresectable HCCs. The purpose of this article is to review HCC imaging appearance after treatment.